Over 700 Total Lots Up For Auction at Three Locations - NC 02/01, NY 02/02, UT 02/03

Getting the facts straight: Clarifying Remanufacturing to Protect Patient Safety Act of 2022

April 19, 2022
HTM Parts And Service
An op-ed by Patrick Hope

Mistakes happen. It’s a fact of life. However, across all aspects of American life, regulations exist to balance the risk of mistakes with the severity of outcomes. When clear, simple uncontroversial measures have the potential to save lives, we expect policymakers to act swiftly.

Such is the case with medical device remanufacturing. In a 2018 report, the U.S. Food & Drug Administration (FDA) concluded that a majority of reports alleging that inadequate “servicing” caused or contributed to adverse events and deaths actually pertained to “remanufacturing” not “servicing.” These egregious remanufacturing activities had escaped oversight, in large part, due to confusion about where the line between servicing and remanufacturing is. In other words, inadvertent mistakes resulting from unclear regulations.

In medicine, not knowing what we don’t know can have devastating consequences — but for problems we do know about with easy solutions, like ensuring proper oversight of remanufacturing, it is imperative for Congress to act. The Clarifying Remanufacturing to Protect Patient Safety Act of 2022 (H.R. 7253) would clarify the definition of remanufacturing as it relates to medical devices to better protect patients by helping educate those who work on these complex medical devices about where the line is for these activities, and ensure they fall under proper FDA oversight.

Here is what this legislation is not. This bill does not change how remanufacturing itself is regulated. Rather, it clarifies remanufacturing in a way that removes ambiguity about which device maintenance activities are of the most concern. The bill maintains remanufacturing is an activity that “significantly” alters how a device functions but provides more concrete examples of what type of activities fit that definition. By doing so, this bill creates transparency for all actors and helps to prevent potential risks from medical device safety or performance changes that happened previously without proper oversight or accountability.

The bill also provides for public education measures to raise awareness of safety concerns and allows responsible actors to come into compliance and put patient safety first. This means responsible parties are given clarity to address existing confusion, and the FDA is given authority to act in the best interest of patients.


Wayne Webster

Is this an article or a Public Relations piece?

April 21, 2022 10:02

The author of this op-ed (opinion piece) is Patrick Hope. In his bio we learn Mr. Hope is the Executive Director of MITA. I'm assuming Mr. Weems works for Mr. Hope at MITA. MITA is the trade association that represents the OEM's. The OEM's pay MITA to represent them. Mr. Hope and Mr. Weems must be compensated by the fees paid by the OEM's to MITA for representation. Mr. Weems claims this is a "Great article..." I think it is not an article. It is a PR piece from MITA, the organization charged with promoting their client's position. I'd be much more impressed if a peer reviewed article with verified facts and figures was presented rather than a Public Relations piece.

Log inor Register

to rate and post a comment


Ted Lucidi

re: Is this an article or a Public Relations piece?

April 22, 2022 10:24

You raise a very important point. Thanks for highlighting this Wayne.

Log inor Register

to rate and post a comment

You Must Be Logged In To Post A Comment